Non ‐parallel anti‐tumour effects of pembrolizumab: a case of cardial tamponade

We present the case of a 70 ‐year‐old man with stage IV lung adenocarcinoma. He was treated with pembrolizumab, a programmed cell death‐1 inhibitor, as a first‐line therapy. After six cycles of pembrolizumab, he suddenly developed cardiac tamponade. With the exception of newly massive malignant pericardial effusion, th e other malignant lesions improved. Pembrolizumab was continued and the patient has shown a durable response for two years. We present the case of a 70 ‐year‐old man with stage IV lung adenocarcinoma. He was treated with pembrolizumab, a programmed cell death‐1 (PD‐1) inhibitor, as a first‐line therapy. After six cycles of pembrolizumab, he suddenly developed cardiac tamponade. With the exception of newly massive malignant pericardial e ffusion, the other malignant lesions improved. Pembrolizumab was continued and the patient has shown a durable response for two years. This is the unique case of late‐onset pericaridial effusion with pembrolizumab, showed discrepant anti‐tumour effects. A proper assessment is crucial to ensure favourable clinical outcomes in patients treated with PD‐1 inhibitor.

Source: Respirology Case Reports - January 31, 2019 Category: Respiratory Medicine Authors: Motoko Tachihara, Masatsugu Yamamoto, Masako Yumura, Asuka Yoshizaki, Kazuyuki Kobayashi, Yoshihiro Nishimura Tags: Case Report Source Type: research